Australia markets open in 2 hours 52 minutes

ChemoCentryx, Inc. (CCXI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
24.41-1.05 (-4.12%)
As of 03:06PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close25.46
Bid24.29 x 1000
Ask24.38 x 1300
Day's range23.80 - 26.40
52-week range9.53 - 70.29
Avg. volume1,474,458
Market cap1.709B
Beta (5Y monthly)1.77
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    ChemoCentryx (CCXI) Tavneos Gets EU Nod for ANCA Vasculitis

    Following approval in the EU, ChemoCentryx (CCXI) plans to launch Tavneos for treating ANCA-associated vasculitis in first-half 2022.

  • Motley Fool

    Why ChemoCentryx Stock Tanked in 2021

    Shares of ChemoCentryx (NASDAQ: CCXI), a mid-cap biopharmaceutical company, fell by a noteworthy 41.2% over the course of 2021, according to data provided by S&P Global Market Intelligence. ANCA-vasculitis is an autoimmune disorder characterized by swelling and damage to small blood vessels. Although the Food and Drug Administration (FDA) ultimately approved Tavneos on Oct. 8, 2021, the drug's fate was far from certain due to a mixed advisory committee (adcom) meeting earlier in the year.

  • Simply Wall St.

    When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Breakeven?

    ChemoCentryx, Inc. ( NASDAQ:CCXI ) is possibly approaching a major achievement in its business, so we would like to...